Background: The ADA and Diabetes UK reported the efficacy of low-carbohydrate diets (LCD) in medical nutrition therapy for blood glucose and lipid management. However, following an LCD may be difficult for many people with diabetes, especially those who consume noodles regularly. To remedy this, we developed a low-available carbohydrate noodle (LACN) using a by-product of Soybean (Glycine max) processing (commonly called “okara”) and Amorphophallus konjac (commonly called Konjac). In this initial study, the effects of the LACN (Figure A) on blood glucose levels (GL) were investigated in Spontaneously Diabetic Torii fatty rats (SDT-fr).
Methods: Male, 5-week-old SDT-fr were allocated into two groups based on diet; Group I was fed standard chow (SC) as a control group (n = 6), while Group II was fed SC with 50% LACN (n = 6). The animals were allowed free access to food for 28 days.
Results: The plasma GL in the LACN group (Group II) were significantly lower than those in the control group (Figure C), in which body weight (BW) gain was observed (Figure B). Our results, in concurrence with other papers, provide evidence that BW increase in Group II was associated with increase in lean body mass, and that the change in muscle mass of SDT-fr was mainly caused by the LACN intake.
Conclusions: LACN might be useful for patients with diabetes or celiac disease who wish to maintain a noodle-based diet.
K. Suruga: None. T. Tomita: None. M. Kobayashi: None. T. Mitsui: None. K. Kadokura: None.